Clinical trials
Completed Hypertension trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
141 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 6 |
| 2009 | 6 |
| 2010 | 12 |
| 2011 | 8 |
| 2012 | 8 |
| 2013 | 1 |
| 2014 | 9 |
| 2015 | 5 |
| 2016 | 5 |
| 2017 | 12 |
| 2018 | 8 |
| 2019 | 8 |
| 2020 | 4 |
| 2021 | 8 |
| 2022 | 6 |
| 2023 | 10 |
| 2024 | 8 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 141 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 7 |
| The George Institute for Global Health, China | 7 |
| Boehringer Ingelheim | 5 |
| Novartis | 4 |
| Sanofi | 4 |
| Shanghai Jiao Tong University School of Medicine | 4 |
| Third Military Medical University | 4 |
| Bayer | 3 |
| China National Center for Cardiovascular Diseases | 3 |
| Lee's Pharmaceutical Limited | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypertension | 141 |
| Cardiovascular Diseases | 10 |
| Diabetes Mellitus | 10 |
| Essential Hypertension | 9 |
| Stroke | 8 |
| Hyperaldosteronism | 7 |
| Obesity | 6 |
| Fibrosis | 4 |
| Sleep Apnea, Obstructive | 4 |
| Cerebrovascular Disorders | 3 |
Trials
Showing 1 to 25 of 141. Each trial links to its page on Pharma Observatory.
41 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.